At a glance
ClinicalIndex Comparison Record- ✓Stage IIIA (T1-3 N2) or Stage IIIB (N3, excluding supraclavicular) non-small cell lung cancer confirmed by biopsy or cytology; Pancoast tumors eligible if mediastinal nodal disease documented
- ✓Mediastinal lymph nodes must be pathologically proven positive by mediastinoscopy, thoracoscopy, Chamberlain procedure, or transbronchial needle aspirate
- ✓Age ≥18 years
- ✓Life expectancy ≥6 months
- ✕Small cell lung cancer or distant metastatic disease
- ✕Clinical or radiographic supraclavicular lymph node involvement
- ✕Bronchioalveolar carcinoma with lobar or multilobar involvement
- ✕Unintentional weight loss >5% within 6 months or Zubrod performance status ≥2
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For Locally Advanced Non-Small Cell Lung Carcinoma
In Brief
A Phase 2 clinical trial evaluating Induction Carboplatin, Induction Paclitaxel, and 4 other interventions for Lung Cancer. Completed, enrolled 60 participants across 22 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving paclitaxel and carboplatin together with radiation therapy before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any tumor cells remaining after surgery. PURPOSE: This phase II trial is studying how well giving paclitaxel and carboplatin together with radiation therapy works in treating patients who are undergoing surgery for stage III non-small cell lung cancer.